Drug survival of biologic agents in patients with psoriatic arthritis from a medical center in southern Taiwan

Drug survival of biologic agents in patients with psoriatic arthritis from a medical center in southern Taiwan

Background: Psoriasis is a chronic inflammatory disease involving the skin and/or joints. Till 2016, there were five biologic agents for psoriatic arthritis treatment in Taiwan: etanercept, adalimumab, golimumab, ustekinumab, and secukinumab. Although European guidelines recommend tumor necrosis fac...

Full description

Bibliographic Details
Main Authors: Sebastian Yu, Yu-Hsiang Tsao, Hung-Pin Tu, Cheng-Che E Lan
Format: Article
Language:English
Published: Wolters Kluwer Medknow Publications 2022-01-01
Series:Dermatologica Sinica
Subjects:
biologic agent
interleukin-17
psoriasis
psoriatic arthritis
tumor necrosis factor-α
interleukin-12/23
Online Access:http://www.dermsinica.org/article.asp?issn=1027-8117;year=2022;volume=40;issue=1;spage=20;epage=27;aulast=Yu

Similar Items

Similar Items